ClinicalTrials.gg

Program

Denosumab

Also written as “denosumab”, “CT-P41” and “AMG 162”.

Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis · Breast Neoplasms · Giant Cell Tumor of Bone · Prostatic Neoplasms, led by 13 companies.

Furthest: phase 4, since Nov 20, 201278 company-led studies, 5 open or runningNext primary completion: Jan 23, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen553 open or runningphase 4since Nov 20, 2012Aug 6, 2002Jan 23, 2027phase 4 · NCT06332014
GlaxoSmithKline50 open or runningphase 3since Oct 20, 2011Oct 20, 2011none ahead
Celltrion30 open or runningphase 3since Feb 12, 2021Aug 11, 2020none ahead
Mabwell (Shanghai) Bioscience30 open or runningphase 3since Jan 18, 2022Mar 12, 2021none ahead
Daiichi Sankyo20 open or runningphase 3since May 16, 2008May 16, 2008none ahead
Fosun Pharma20 open or runningphase 3since Apr 23, 2022Aug 27, 2020none ahead
Shanghai Biomabs Pharmaceutical20 open or runningphase 3since Oct 15, 2020Apr 18, 2019none ahead
aryogen-pharmed-co10 open or runningphase 3since Sep 19, 2017Sep 19, 2017none ahead
Hamad Medical10 open or runningphase 3since Jan 22, 2017Jan 22, 2017none ahead
lambda-therapeutic-research-ltd11 open or runningphase 3since Jun 7, 2022Jun 7, 2022none ahead
Luye Pharma Group11 open or runningphase 3since May 2, 2023May 2, 2023none ahead
Samsung Bioepis10 open or runningphase 1since Nov 3, 2020Nov 3, 2020none ahead
Taizhou Mabtech Pharmaceutical10 open or runningphase 1since Apr 7, 2024Apr 7, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Aug 9, 2007.

  1. Oct 7, 2020Phase 4 study in Giant Cell Tumor of BoneAmgen · NCT04586660 · 36 enrolled · China, Taiwan
  2. Oct 15, 2020Phase 3 study in Osteoporosis, PostmenopausalShanghai Biomabs Pharmaceutical · NCT04591275 · 278 enrolled · China
  3. Nov 3, 2020Samsung Bioepis's first study: phase 1 study in HealthyNew to Samsung BioepisSamsung Bioepis · NCT04621318 · 168 enrolled · United States, France
  4. Feb 12, 2021Phase 3 study in Postmenopausal Women With OsteoporosisCelltrion · NCT04757376 · 479 enrolled · Estonia, Latvia, Poland and more
  5. Mar 12, 2021Mabwell (Shanghai) Bioscience's first study: phase 1 study in Osteoporosis, PostmenopausalNew to Mabwell (Shanghai) BioscienceMabwell (Shanghai) Bioscience · NCT04798313 · 120 enrolled · China
  6. Jan 18, 2022Phase 3 study in Osteoporosis, PostmenopausalMabwell (Shanghai) Bioscience · NCT05215977 · 448 enrolled · China
  7. Apr 23, 2022Phase 3 study in PostmenopausalFosun Pharma · NCT05352516 · 514 enrolled · China
  8. Jun 7, 2022lambda-therapeutic-research-ltd's first study: phase 3 study in Osteoporosis, PostmenopausalNew to lambda-therapeutic-research-ltdlambda-therapeutic-research-ltd · NCT05419427 · 552 planned · India
  9. May 2, 2023Luye Pharma Group's first study: phase 3 study in Osteoporosis, PostmenopausalNew to Luye Pharma GroupLuye Pharma Group · NCT05853354 · 392 enrolled · United States, Bulgaria, Czechia and more
  10. Sep 7, 2023Phase 1 study in Healthy SubjectCelltrion · NCT06037395 · 154 enrolled · Korea, Republic of
  11. Mar 19, 2024Phase 4 study in OsteoporosisAmgen · NCT06332014 · 102 enrolled · China
  12. Apr 7, 2024Taizhou Mabtech Pharmaceutical's first study: phase 1 study in Healthy VolunteersNew to Taizhou Mabtech PharmaceuticalTaizhou Mabtech Pharmaceutical · NCT06361355 · 128 enrolled · China
  13. Sep 5, 2024Phase 4 study in Glucocorticoid-induced OsteoporosisAmgen · NCT06588153 · 102 enrolled · China
  14. Dec 9, 2024Phase 3 study in Postmenopausal Women OsteoporosisMabwell (Shanghai) Bioscience · NCT06804590 · 280 enrolled · China

Ahead

  1. Jan 23, 2027Primary completion: phase 4 study in OsteoporosisAmgen · NCT06332014
  2. Apr 27, 2027Primary completion: phase 4 study in Glucocorticoid-induced OsteoporosisAmgen · NCT06588153
  3. Mar 7, 2028Primary completion: phase 4 study in Giant Cell Tumor of BoneAmgen · NCT04586660

TargetBeta

TNFSF11 →read by rule
“A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity”NCIt, by rule
“Tumor necrosis factor ligand superfamily member 11 inhibitor”ChEMBL 37, by rule

Other programs on TNFSF11

ProgramCompanyFurthest phaseStudies
QL1206ruleQilu Pharmaceuticalphase 35
SHR-2017Jiangsu HengRui Medicinephase 12

Studies

The newest 60 of 78 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06804590Postmenopausal Women Osteoporosis · China3CompletedMabwell (Shanghai) BioscienceApr 24, 2026280
NCT06588153Glucocorticoid-induced Osteoporosis · China4Active, not recruitingAmgenApr 27, 2027102
NCT06361355Healthy Volunteers · China1CompletedTaizhou Mabtech PharmaceuticalJun 3, 2024128
NCT06332014Osteoporosis · China4Active, not recruitingAmgenJan 23, 2027102
NCT06037395Healthy Subject · Korea, Republic of1CompletedCelltrionOct 20, 2022154
NCT05853354Osteoporosis, Postmenopausal · United States, Bulgaria, Czechia and more3Active, not recruitingLuye Pharma GroupJul 30, 2025392
NCT05419427Osteoporosis, Postmenopausal · India3Recruitinglambda-therapeutic-research-ltdSep 11, 2024552
NCT05352516Postmenopausal · China3CompletedFosun PharmaDec 17, 2023514
NCT05215977Osteoporosis, Postmenopausal · China3CompletedMabwell (Shanghai) BioscienceSep 27, 2021448
NCT04798313Osteoporosis, Postmenopausal · China1CompletedMabwell (Shanghai) BioscienceDec 7, 2020120
NCT04757376Postmenopausal Women With Osteoporosis · Estonia, Latvia, Poland and more3CompletedCelltrionMay 18, 2023479
NCT04621318Healthy · United States, France1CompletedSamsung BioepisNov 9, 2022168
NCT04591275Osteoporosis, Postmenopausal · China3CompletedShanghai Biomabs PharmaceuticalNov 1, 2024278
NCT04586660Giant Cell Tumor of Bone · China, Taiwan4Active, not recruitingAmgenMar 7, 202836
NCT04534582Healthy Male Volunteers · China1CompletedFosun PharmaSep 12, 2023252
NCT04512872Healthy Male Subjects · Australia1CompletedCelltrionMay 4, 202130
NCT03925051Osteoporosis, Postmenopausal · China1CompletedShanghai Biomabs PharmaceuticalMar 21, 2020132
NCT03822078Osteoporosis1CompletedAmgenDec 24, 200445
NCT03638128Osteogenesis Imperfecta · United States, Australia, Belgium and more3TerminatedAmgenMar 28, 202275
NCT03301857Giant Cell Tumor of Bone · United States, Australia, France and more4CompletedAmgenJul 27, 202385
NCT03293108Osteoporosis · Iran, Islamic Republic of3UNKNOWNaryogen-pharmed-coSep 30, 2020190
NCT03164928Osteoporosis · United States, Australia, Belgium and more3CompletedAmgenDec 13, 202124
NCT03040765beta-Thalassemia · Qatar3TerminatedHamad MedicalApr 8, 201917
NCT02352753Osteogenesis Imperfecta · United States, Australia, Belgium and more3TerminatedAmgenMar 26, 2022153
NCT02157948Osteoporosis, Postmenopausal · United States, Canada, Denmark and more3CompletedAmgenJul 2015394
NCT02135640Osteoporosis · China1CompletedGlaxoSmithKlineFeb 17, 201564
NCT02101164Bone Diseases4WithdrawnAmgenNov 20140
NCT02099461Healthy Volunteer, Female, Breast · United States1CompletedAmgenJul 201482
NCT02053753Healthy Volunteer · United States1CompletedAmgenAug 2014146
NCT02014467Osteoporosis, Postmenopausal · China3CompletedGlaxoSmithKlineAug 2015486
NCT01973569Arthritis, Rheumatoid · Japan–CompletedDaiichi SankyoDec 2015679
NCT01951586Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2CompletedAmgenJul 29, 2016226
NCT01920568Fractures, Bone · China, Singapore, Taiwan3CompletedGlaxoSmithKlineFeb 2015487
NCT01869686Healthy Volunteer · United States1CompletedAmgenSep 201312
NCT01824342Castrate-resistant Prostate Cancer · Czech Republic, United Kingdom3CompletedAmgenFeb 201418
NCT01732770Osteoporosis, Postmenopausal · United States, Australia, Belgium and more4CompletedAmgenJan 7, 2015643
NCT01575873Steroid-induced Osteopor, Glucocorticoid-induced Ostepor · United States, Argentina, Belgium and more3CompletedAmgenJun 21, 2016795
NCT01495000Osteoporosis, Postmenopausal · India3CompletedGlaxoSmithKlineFeb 2013250
NCT01457950Osteoporosis, Postmenopausal · Korea, Republic of3CompletedGlaxoSmithKlineDec 2012135
NCT01464931Renal Insufficiency · United States1CompletedAmgenJan 201332
NCT01419717Neoplasms · Argentina, Austria, Belgium and more3CompletedAmgenAug 10, 2018129
NCT01345019Neoplasms · United States, Australia, Austria and more3CompletedAmgenJul 19, 20161,718
NCT01294397Bone Diseases, Metabolic · United States1TerminatedAmgenJan 201619
NCT01221727Osteoporosis, Postmenopausal1CompletedAmgenJul 201130
NCT01077154Breast Neoplasms · United States, Argentina, Australia and more3TerminatedAmgenAug 31, 20174,509
NCT00980174Bone Diseases, Metabolic3CompletedAmgenJun 21, 2011242
NCT00950911Multiple Myeloma · Czech Republic, United Kingdom3CompletedAmgenFeb 201235
NCT00936897Osteoporosis, Postmenopausal3CompletedAmgenNov 2011833
NCT00925600Neoplasms · United States, Australia, Bulgaria and more3CompletedAmgenMay 12, 2016769
NCT00919711Osteoporosis3CompletedAmgenDec 21, 2011870
NCT00896532Bone Diseases, Metabolic2CompletedAmgenFeb 21, 2011419
NCT00896454Breast Neoplasms · United States, Canada, France and more2CompletedAmgenSep 13, 201233
NCT00890981Bone Diseases, Metabolic3CompletedAmgenJun 201079
NCT00838201Neoplasms · United States, Canada, Finland and more3CompletedAmgenMay 3, 2012384
NCT00680953Osteoporosis · Japan3CompletedDaiichi SankyoJun 20121,262
NCT00680992Neoplasms · United States, Australia, Austria and more2CompletedAmgenMay 17, 2018535
NCT00556374Breast Neoplasms · Austria, Sweden3CompletedAmgenOct 7, 20143,420
NCT00523341Bone Diseases, Metabolic3CompletedAmgenJul 19, 20154,550
NCT00518531Osteoporosis3CompletedAmgenJun 1, 2009250
NCT00515463Bone Diseases, Metabolic3CompletedAmgenMar 2008311

How it is read

Names in the registry

  • “Denosumab”, 41 entries
  • “denosumab”, 10 entries
  • “CT-P41”, 3 entries
  • “AMG 162”, 3 entries
  • “Prolia®”, 2 entries

Codes read as this program: CMAB807.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.